Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients With Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase Studies
Keun-Wook Lee·Funda Meric-Bernstam·Do-Youn Oh·Muralidhar Beeram·Toshihiko Doi·Kay T. Yeung·T. Samuel Nached·Kavita Shah·Douglas S. Fuller·Diana Shpektor·Emanuele Loro·Elena Elimova
Although the sample size is small, these findings support the clinical benefit of zanidatamab treatment for HER2-positive SGC.